Travere Therapeutics Files 2024 10-K
Ticker: TVTX · Form: 10-K · Filed: Feb 21, 2025 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | 10-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
Travere Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Travere Therapeutics, Inc. filed its 2024 10-K on February 21, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Retrophin, Inc., is focused on pharmaceutical preparations. Key financial details and operational highlights for the period are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Travere Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Travere Therapeutics is subject to significant risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 001-36257 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Travere Therapeutics, Inc. (company) — Filer
- Retrophin, Inc. (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 2025-02-21 (date) — Filing date
- San Diego, CA (location) — Business address
FAQ
What were Travere Therapeutics' primary business activities during the fiscal year 2024?
The filing indicates Travere Therapeutics operates within the Pharmaceutical Preparations industry (SIC Code 2834) and focuses on clinical trials and related pharmaceutical activities.
When did Travere Therapeutics officially change its name from Retrophin, Inc.?
The company's name was changed from Retrophin, Inc. on February 20, 2013.
What is the business address of Travere Therapeutics?
The business address is 3611 Valley Centre Dr, Suite 300, San Diego, CA 92130.
What is the filing date of this 10-K report?
This 10-K report was filed on February 21, 2025.
What is the fiscal year end date covered by this 10-K filing?
The fiscal year end date covered by this filing is December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 21, 2025 regarding Travere Therapeutics, Inc. (TVTX).